Indochina Healthcare Limited (IHL) was formed in 1994 by Mr. S. Douglas Sheldon, a former multinational pharmaceutical company executive with many years of experience in Asia. The objective of IHL was to provide high quality and good value medical products to patients in South East Asia (Indochina) with a particular focus on providing medicines to Thai patients.

Currently IHL’s main business is the registration, distribution and marketing of prescription medicines to Thai hospitals (both public and private). These medicines are of high quality in that they are approved for use in developed markets with a high standard of GMP inspection – such as USA, EU and Australia; where they are recognized as equivalent to the original brand name product. This provides confidence to the medical profession that their patients are receiving the best quality treatment; at a reasonable cost.

IHL sources medicines from its Joint Venture partner, Hospira of the USA, as well as supplying medicines from other high quality suppliers. Currently IHL’s medicines are concentrated in the oncology, critical care and anti-infective therapeutic categories.

IHL also offer a range of market leading IV infusion systems and other medical devices; mainly produced by Hospira.

IHL continues to explore opportunities to source high quality medicines and medical devices for Thai patients and will expand the range of medicines to additional therapeutic categories.